vTv Therapeutics (NASDAQ:VTVT) Posts Quarterly Earnings Results, Misses Expectations By $0.08 EPS

vTv Therapeutics (NASDAQ:VTVT) released its quarterly earnings data on Thursday. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.08), Zacks reports.

vTv Therapeutics Stock Performance

Shares of NASDAQ VTVT opened at $35.37 on Friday. The company has a market capitalization of $139.36 million, a P/E ratio of -33.37 and a beta of 0.28. vTv Therapeutics has a 52-week low of $14.00 and a 52-week high of $44.00. The company’s 50 day moving average price is $33.40 and its 200-day moving average price is $34.80.

Hedge Funds Weigh In On vTv Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC raised its position in shares of vTv Therapeutics by 84.3% in the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after acquiring an additional 12,896 shares in the last quarter. 683 Capital Management LLC bought a new stake in vTv Therapeutics in the fourth quarter worth approximately $731,000. Finally, Goldman Sachs Group Inc. acquired a new position in vTv Therapeutics in the fourth quarter valued at approximately $221,000. Institutional investors own 17.51% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on VTVT. Wall Street Zen lowered shares of vTv Therapeutics from a “buy” rating to a “sell” rating in a report on Saturday. Rodman & Renshaw initiated coverage on shares of vTv Therapeutics in a report on Tuesday, June 30th. They set a “buy” rating and a $67.00 price target on the stock. BTIG Research boosted their price objective on shares of vTv Therapeutics from $49.00 to $57.00 and gave the stock a “buy” rating in a research note on Thursday, July 16th. Weiss Ratings upgraded vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a report on Monday, May 18th. Finally, HC Wainwright lowered their target price on vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating for the company in a research report on Thursday. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, vTv Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $55.83.

Key vTv Therapeutics News

Here are the key news stories impacting vTv Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and a $42 price target, implying potential upside from recent trading levels. The continued bullish rating may be supporting the stock despite the firm’s estimate reductions. HC Wainwright price target report
• Neutral Sentiment: vTv Therapeutics reported second-quarter 2026 earnings of a $1.05-per-share loss, compared with the expected $0.97 loss. The results missed estimates, but investors are also reviewing the company’s broader corporate update and development outlook. vTv Therapeutics second-quarter results and corporate update
• Negative Sentiment: HC Wainwright reduced its EPS forecast for fiscal 2026 to a $0.97 loss from a prior expectation of $0.02 profit. It also lowered estimates for the third and fourth quarters of 2026 and for fiscal 2027 through 2030, signaling expectations for greater or more prolonged losses. The firm nevertheless kept its Buy rating and $42 target. HC Wainwright earnings estimate revisions
• Negative Sentiment: Wall Street Zen downgraded VTVT to Sell, adding a bearish counterpoint to HC Wainwright’s continued Buy recommendation. Wall Street Zen downgrade

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.